Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
Latest Information Update: 20 Oct 2023
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REMIT-iGL
- 20 Oct 2023 Results examining whether remission can be achieved by combining lifestyle approaches and short-term intensive glucose-lowering therapy, published in the Diabetes, Obesity and Metabolism
- 29 Jun 2021 Primary endpoint (The first occurrence of diabetes relapse) has been met, as per results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 29 Jun 2021 Results (n=160) assessing induction of diabetes remission following a short-term treatment with insulin glargine, lixisenatide and metformin and changes in exercise and dietary behaviours, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.